Compare four COVID-19 vaccines. Who developed them and how many times do you need to vaccinate?

While residents of Novosibirsk are being vaccinated with the Moscow vaccine – “Sputnik V”. Four vaccines against coronavirus compared in Novosibirsk

Three vaccines against coronavirus have already been developed in Russia, one of them is near Novosibirsk. Another drug is in the research stage.

How do these drugs differ from each other? Who developed them? How did the clinical trials go? We have collected all the known information about these vaccines.

What is known about the Sputnik V vaccine

The registration of the first vaccine, Sputnik V, became known on 11 August. Later, a representative of the Ministry of Health of the NSO said that 10 thousand doses would be delivered to the region in early November. But something went wrong with the supplies – at first only 42 vaccines were brought to the region.

The Ministry of Health explained this by the fact that the drug will be delivered fractionally due to special storage conditions. The NHS prepared a photo report on how the first doctors were vaccinated – they talked about their feelings. Mass vaccination of the population against coronavirus began in January.

What is known about the EpiVacCorona vaccine

The first phase of vaccine trials from the Vector Center began on July 27 last year. And in October the drug EpiVacCorona was registered. For post-registration tests, which should last six months, 43 thousand volunteers were looking for. Vaccination in the Novosibirsk region began on December 16. First of all, the drug was received by doctors and teachers.

What is known about the vaccine “KoviVac”

The third coronavirus vaccine in Russia, called KoviVac, was registered at the end of February. It was developed at the Chumakov Federal Research and Development Center for Immunobiological Preparations of the Russian Academy of Sciences, which is located in Moscow. The first 120 thousand doses are planned to be sent to civilian circulation in March this year.

Earlier, the volunteers who were vaccinated with the vaccine against “Vector”, and scientists had questions about this drug. The NGS tried to figure out why EpiVacCorona raises doubts.

What is known about the FMBA vaccine

According to the website Stopkoronavirus.rf, the FMBA vaccine has passed the first stage of preclinical screening studies. Experts have tested its immunogenicity, primary safety and other indicators. Clinical trials are scheduled to begin in July and will take several months.

This vaccine does not target the S protein, but other protein components of the virus. It causes the development of immunity at the cellular level. Due to this, according to research, immunity can last for years.


This week, March 4, it became known that Novosibirsk scientists predicted a new peak in the incidence of coronavirus. And they named the estimated date when the pandemic will end.

If you are going to get vaccinated against coronavirus, then look at the NHS instructions: how to get yourself vaccinated against covid – instructions in 10 cards.

Leave a Reply

Your email address will not be published.